Media Summary: Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, discusses the role of In this segment, Keith McCrae, MD, and Ivy Altomare, MD, describe the pathology of idiopathic thrombocytopenic purpura (ITP) ... Ivy Altomare, MD, and Terry Gernsheimer, MD, provide an overview on the use of
Thrombopoietin Receptor Agonists - Detailed Analysis & Overview
Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, discusses the role of In this segment, Keith McCrae, MD, and Ivy Altomare, MD, describe the pathology of idiopathic thrombocytopenic purpura (ITP) ... Ivy Altomare, MD, and Terry Gernsheimer, MD, provide an overview on the use of In this segment, Keith McCrae, MD, and Ivy Altomare, MD, compare Ivy Altomare, MD; Keith R. McCrae, MD; and Terry Gernsheimer, MD, discuss clinical considerations for treating appropriate adult ... Panelists consider how to decide between the available
Jerry Spivak, MD, Johns Hopkins University School of Medicine, Baltimore, MD, discusses the potential of the Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, comments on the current treatment landscape for patients ... Dr. Fertrin on the FDA Approval of Avatrombopag in ITP Barbara Skopec, MD, PhD, University Medical Centre Ljubljana, Ljublyjana, Slovenia, shares which abstracts she is most looking ... James B. Bussel, MD, comments on the duration for platelets to begin to recover with Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, discusses emerging treatment options for refractory ...
This is a live recording from January 30th, 2026, featuring Dr. Kristin Shimano and moderated by Dr. Amanda Grimes. Barbara Skopec, MD, PhD, University Medical Centre Ljubljana, Ljubljana, Slovenia, shares the findings of a post-hoc analysis of ... ... to the extracellular domains of Throop potin James B. Bussel, MD, describes the second-line treatment options for patients with immune thrombocytopenia. For more ...
